PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
作者： M Frattini , P Saletti , E Romagnani , V Martin , F Molinari
关键词:
摘要: … affect the clinical response in cetuximab-treated metastatic colorectal cancer (mCRC) patients. Twenty-seven cetuximab-treated mCRC patients were evaluated for drug response and …
nature.com
sci-hub.se 参考文章(28)
H. Wilke, R. Glynne-Jones, J. Thaler, A. Adenis, P. Preusser, E. Aranda Aguilar, M. Aapro, N. Van Den Berg, S. Eggleton, S. Siena, MABEL—A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer Journal of Clinical Oncology. ,vol. 24, pp. 3549- 3549 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3549
D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky, R. Mayer, A. Venook, D. Niedzwiecki, Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results Journal of Clinical Oncology. ,vol. 24, pp. 3509- 3509 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3509
Sufi Mary Thomas, Jennifer Rubin Grandis, Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews. ,vol. 30, pp. 255- 268 ,(2004) , 10.1016/J.CTRV.2003.10.003
Pier Paolo Pandolfi, Breast cancer--loss of PTEN predicts resistance to treatment. The New England Journal of Medicine. ,vol. 351, pp. 2337- 2338 ,(2004) , 10.1056/NEJMCIBR043143
Leopoldo Sarli, Lorena Bottarelli, Giovanni Bader, Domenico Iusco, Silvia Pizzi, Renato Costi, Tiziana DʼAdda, Marco Bertolani, Luigi Roncoroni, Cesare Bordi, Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Diseases of The Colon & Rectum. ,vol. 47, pp. 1467- 1482 ,(2004) , 10.1007/S10350-004-0628-6
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Eric R. Fearon, Bert Vogelstein, A genetic model for colorectal tumorigenesis Cell. ,vol. 61, pp. 759- 767 ,(1990) , 10.1016/0092-8674(90)90186-I
Astrid Mayer, Masafumi Takimoto, Elke Fritz, Georgine Schellander, Klaus Kofler, Heinz Ludwig, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer Cancer. ,vol. 71, pp. 2454- 2460 ,(1993) , 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2
Christian Kersting, Jens Packeisen, Benedikt Leidinger, Burkhard Brandt, Reinhard von Wasielewski, Wilfried Winkelmann, Paul J van Diest, Georg Gosheger, Horst Bürger, Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas Journal of Clinical Pathology. ,vol. 59, pp. 585- 590 ,(2006) , 10.1136/JCP.2005.028373
J Baselga, The EGFR as a target for anticancer therapy--focus on cetuximab. European Journal of Cancer. ,vol. 37, pp. 16- 22 ,(2001) , 10.1016/S0959-8049(01)00233-7